This contributor column discusses a recent study that shows the 340B Program’s explosive growth is overwhelmingly due to utilization increases, not price.
Rory Martin, PhD
Advertisement
Rory Martin, PhD, Gross to Net and 340B Analytics & Thought Leadership, IQVIA Market Access Technology Solutions
ORCID ID: 0000-0002-7216-4245
Articles by Rory Martin, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Prescription Access Crisis: 40% of GLP-1 RA Rx Are Unfilled
2
New WHO Reports Sounds Alarm on Antimicrobial Resistance
3
Value-Based Care Offers Solutions to Patient Access Challenges: Brian Mulherin, MD
4
Guideline-Directed Medical Therapies in Heart Failure
5
